Fluvoxamine pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "fluvoxamine pharmacology"
Fluvoxamine Pharmacology: Mechanism of Action and Selectivity
Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that works by potently and specifically inhibiting the reuptake of serotonin (5-hydroxytryptamine, 5-HT) in the brain, leading to increased serotonin levels in synaptic spaces and enhanced serotonergic neurotransmission Claassen1983Benfield1986Dieckmann2025+1 MORE. Unlike many other antidepressants, fluvoxamine does not significantly affect the reuptake of noradrenaline and has minimal affinity for cholinergic receptors, which contributes to its favorable side effect profile Claassen1983Benfield1986. Studies show that fluvoxamine preferentially increases extracellular serotonin in the raphe nuclei, the region where serotonergic neurons originate, more than in the frontal cortex .
Pharmacokinetics and Metabolism of Fluvoxamine
Fluvoxamine is well absorbed in animal models, with similar metabolic pathways observed across different species such as rats, dogs, hamsters, mice, and rabbits . The metabolites of fluvoxamine are inactive regarding aminergic uptake processes, meaning they do not contribute to its antidepressant effects . Pharmacokinetic studies also indicate that fluvoxamine has a good absorption profile and does not show specific hepatic toxicity .
Drug Interactions: Cytochrome P450 Inhibition
A key pharmacological property of fluvoxamine is its potent inhibition of the cytochrome P4501A2 (CYP1A2) enzyme . This inhibition can lead to significant drug interactions with medications metabolized by CYP1A2, such as theophylline and imipramine, making it important to monitor for interactions when fluvoxamine is prescribed alongside these drugs .
Therapeutic Efficacy and Safety Profile
Fluvoxamine has demonstrated consistent efficacy in treating depression, showing superiority over placebo and comparable effectiveness to other antidepressants, including tricyclic antidepressants (TCAs) and other SSRIs Benfield1986Dieckmann2025. It is associated with fewer anticholinergic and cardiovascular side effects than TCAs, making it a suitable alternative, especially for patients with cardiovascular concerns or those who cannot tolerate TCAs Benfield1986Dieckmann2025. However, fluvoxamine may cause a higher incidence of nausea and vomiting compared to some other antidepressants .
Additional Pharmacological Effects: Anti-Inflammatory and Neuroprotective Actions
Beyond its antidepressant activity, fluvoxamine has shown anti-inflammatory and neuroprotective properties in various animal models. It can reduce inflammation and demyelination in models of multiple sclerosis by promoting neural stem cell proliferation and differentiation, particularly toward oligodendrocytes . Fluvoxamine also attenuates neuroinflammation and improves neurological outcomes in traumatic brain injury models by inhibiting immune cell infiltration and promoting anti-inflammatory microglial phenotypes . In autoimmune and inflammatory disease models, fluvoxamine reduces pro-inflammatory cytokines and shows potential as an anti-arthritic and anti-fibrotic agent Ahsan2022Zou2024Xie2022.
Conclusion
Fluvoxamine is a selective serotonin reuptake inhibitor with a distinct pharmacological profile, characterized by potent serotonin reuptake inhibition, minimal effects on other neurotransmitter systems, and strong inhibition of CYP1A2. It is effective and generally well-tolerated in the treatment of depression, with additional anti-inflammatory and neuroprotective effects observed in preclinical studies. These properties support its clinical utility in depression and suggest potential for broader therapeutic applications.
Sources and full results
Most relevant research papers on this topic